BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Morelon E, Stern M, Israël-Biet D, Correas JM, Danel C, Mamzer-Bruneel MF, Peraldi MN, Kreis H. Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients. Transplantation. 2001;72:787-790. [PMID: 11571438 DOI: 10.1097/00007890-200109150-00008] [Cited by in Crossref: 214] [Cited by in F6Publishing: 170] [Article Influence: 10.7] [Reference Citation Analysis]
Number Citing Articles
1 Ventura-Aguiar P, Campistol JM, Diekmann F. Safety of mTOR inhibitors in adult solid organ transplantation. Expert Opin Drug Saf. 2016;15:303-319. [PMID: 26667069 DOI: 10.1517/14740338.2016.1132698] [Cited by in Crossref: 53] [Cited by in F6Publishing: 47] [Article Influence: 10.6] [Reference Citation Analysis]
2 Schlesinger C, Koss MN. The Organizing Pneumonias: A Critical Review of Current Concepts and Treatment. Treatments in Respiratory Medicine 2006;5:193-206. [DOI: 10.2165/00151829-200605030-00005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
3 Pham PT, Pham PC, Danovitch GM, Ross DJ, Gritsch HA, Kendrick EA, Singer J, Shah T, Wilkinson AH. Sirolimus-associated pulmonary toxicity. Transplantation. 2004;77:1215-1220. [PMID: 15114088 DOI: 10.1097/01.TP.0000118413.92211.B6] [Cited by in Crossref: 217] [Cited by in F6Publishing: 51] [Article Influence: 12.8] [Reference Citation Analysis]
4 Stewart DB, Hollenbeak C, Boltz M. Renal transplant status in patients undergoing colorectal surgery: Is immunosuppression safer than kidney disease? Surgery 2012;152:537-49. [DOI: 10.1016/j.surg.2012.07.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
5 Filippone EJ, Carson JM, Beckford RA, Jaffe BC, Newman E, Awsare BK, Doria C, Farber JL. Sirolimus-induced pneumonitis complicated by pentamidine-induced phospholipidosis in a renal transplant recipient: a case report. Transplant Proc 2011;43:2792-7. [PMID: 21911165 DOI: 10.1016/j.transproceed.2011.06.060] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
6 Boots JM, Christiaans MH, van Hooff JP. Effect of immunosuppressive agents on long-term survival of renal transplant recipients: focus on the cardiovascular risk. Drugs. 2004;64:2047-2073. [PMID: 15341497 DOI: 10.2165/00003495-200464180-00004] [Cited by in Crossref: 100] [Cited by in F6Publishing: 83] [Article Influence: 5.9] [Reference Citation Analysis]
7 Garrean S, Massad MG, Tshibaka M, Hanhan Z, Caines AE, Benedetti E. Sirolimus-associated interstitial pneumonitis in solid organ transplant recipients. Clin Transplant 2005;19:698-703. [PMID: 16146565 DOI: 10.1111/j.1399-0012.2005.00356.x] [Cited by in Crossref: 73] [Cited by in F6Publishing: 61] [Article Influence: 4.6] [Reference Citation Analysis]
8 Debray D, Furlan V, Baudouin V, Houyel L, Lacaille F, Chardot C. Therapy for acute rejection in pediatric organ transplant recipients. Paediatr Drugs 2003;5:81-93. [PMID: 12529161 DOI: 10.2165/00128072-200305020-00002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
9 Conti F, Morelon E, Calmus Y. Immunosuppressive therapy in liver transplantation. Journal of Hepatology 2003;39:664-78. [DOI: 10.1016/s0168-8278(03)00428-8] [Cited by in Crossref: 27] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
10 Frija J, Joly D, Knebelmann B, Dusser D, Burgel P. Everolimus-related organizing pneumonia: a report establishing causality. Invest New Drugs 2012;30:1244-7. [DOI: 10.1007/s10637-010-9624-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
11 Höcker B, Tönshoff B. Calcineurin inhibitor-free immunosuppression in pediatric renal transplantation: a viable option? Paediatr Drugs. 2011;13:49-69. [PMID: 21162600 DOI: 10.2165/11538530-000000000-00000] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
12 Thaunat O, Beaumont C, Chatenoud L, Lechaton S, Mamzer-bruneel M, Varet B, Kreis H, Morelon E. Anemia after Late Introduction of Sirolimus May Correlate with Biochemical Evidence of a Chronic Inflammatory State: . Transplantation 2005;80:1212-9. [DOI: 10.1097/01.tp.0000179106.07382.6a] [Cited by in Crossref: 75] [Cited by in F6Publishing: 67] [Article Influence: 4.7] [Reference Citation Analysis]
13 Fantus D, Rogers NM, Grahammer F, Huber TB, Thomson AW. Roles of mTOR complexes in the kidney: implications for renal disease and transplantation. Nat Rev Nephrol 2016;12:587-609. [PMID: 27477490 DOI: 10.1038/nrneph.2016.108] [Cited by in Crossref: 85] [Cited by in F6Publishing: 71] [Article Influence: 17.0] [Reference Citation Analysis]
14 Lopez P, Kohler S, Dimri S. Interstitial Lung Disease Associated with mTOR Inhibitors in Solid Organ Transplant Recipients: Results from a Large Phase III Clinical Trial Program of Everolimus and Review of the Literature. J Transplant 2014;2014:305931. [PMID: 25580277 DOI: 10.1155/2014/305931] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
15 Ahya VN, Kawut SM. Noninfectious Pulmonary Complications After Lung Transplantation. Clinics in Chest Medicine 2005;26:613-22. [DOI: 10.1016/j.ccm.2005.06.006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
16 Kuypers DRJ. Benefit-Risk Assessment of Sirolimus in Renal Transplantation: . Drug Safety 2005;28:153-81. [DOI: 10.2165/00002018-200528020-00006] [Cited by in Crossref: 73] [Cited by in F6Publishing: 62] [Article Influence: 4.6] [Reference Citation Analysis]
17 Weir MR, Diekmann F, Flechner SM, Lebranchu Y, Mandelbrot DA, Oberbauer R, Kahan BD. mTOR inhibition: the learning curve in kidney transplantation: mTOR inhibition and kidney transplantation. Transplant International 2010;23:447-60. [DOI: 10.1111/j.1432-2277.2010.01051.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 2.2] [Reference Citation Analysis]
18 Dean PG, Lund WJ, Larson TS, Prieto M, Nyberg SL, Ishitani MB, Kremers WK, Stegall MD. Wound-healing complications after kidney transplantation: a prospective, randomized comparison of sirolimus and tacrolimus. Transplantation. 2004;77:1555-1561. [PMID: 15239621 DOI: 10.1097/01.tp.0000123082.31092.53] [Cited by in Crossref: 247] [Cited by in F6Publishing: 44] [Article Influence: 14.5] [Reference Citation Analysis]
19 Diekmann F, Campistol JM. Conversion from calcineurin inhibitors to sirolimus in chronic allograft nephropathy: benefits and risks. Nephrology Dialysis Transplantation 2006;21:562-8. [DOI: 10.1093/ndt/gfi336] [Cited by in Crossref: 60] [Cited by in F6Publishing: 43] [Article Influence: 3.8] [Reference Citation Analysis]
20 Amigues L, Klouche K, Massanet P, Gaillard N, Garrigue V, Beraud JJ, Mourad G. Sirolimus-associated acute respiratory distress syndrome in a renal transplant recipient. Transplant Proc. 2005;37:2830-2831. [PMID: 16182823 DOI: 10.1016/j.transproceed.2005.05.016] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
21 Banerjee SK, Santhanakrishnan K, Tsui S, Parameshwar J, Parmar J. Cavitatory lung disease in thoracic transplant recipients receiving sirolimus. J Heart Lung Transplant 2012;31:548-51. [PMID: 22397867 DOI: 10.1016/j.healun.2012.02.010] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
22 Hamour IM, Mittal TK, Bell AD, Banner NR. Reversible Sirolimus-associated Pneumonitis after Heart Transplantation. The Journal of Heart and Lung Transplantation 2006;25:241-4. [DOI: 10.1016/j.healun.2005.08.022] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 1.7] [Reference Citation Analysis]
23 Narotzky S, Kennedy CC, Maldonado F. An unusual cause of respiratory failure in a 25-year-old heart and lung transplant recipient. Chest 2015;147:e185-8. [PMID: 25940262 DOI: 10.1378/chest.14-1443] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
24 Omarini C, Thanopoulou E, Johnston SR. Pneumonitis and pulmonary fibrosis associated with breast cancer treatments. Breast Cancer Res Treat 2014;146:245-58. [PMID: 24929676 DOI: 10.1007/s10549-014-3016-5] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 3.6] [Reference Citation Analysis]
25 Lindenfeld JA, Simon SF, Zamora MR, Cool CD, Wolfel EE, Lowes BD, Ireland N, Keller K, Frisk R, Stepien L, Cleveland JC, Zolty R. BOOP is Common in Cardiac Transplant Recipients Switched from a Calcineurin Inhibitor to Sirolimus. Am J Transplant 2005;5:1392-6. [DOI: 10.1111/j.1600-6143.2005.00849.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 1.6] [Reference Citation Analysis]
26 Rehm B, Keller F, Mayer J, Stracke S. Resolution of sirolimus-induced pneumonitis after conversion to everolimus. Transplant Proc 2006;38:711-3. [PMID: 16647451 DOI: 10.1016/j.transproceed.2006.01.052] [Cited by in Crossref: 45] [Cited by in F6Publishing: 39] [Article Influence: 3.0] [Reference Citation Analysis]
27 Fernandes-silva G, Ivani de Paula M, Rangel ÉB. mTOR inhibitors in pancreas transplant: adverse effects and drug-drug interactions. Expert Opinion on Drug Metabolism & Toxicology 2017;13:367-85. [DOI: 10.1080/17425255.2017.1239708] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
28 Truong U, Moon-grady AJ, Butani L. Cardiac tamponade in a pediatric renal transplant recipient on sirolimus therapy. Pediatric Transplantation 2005;9:541-4. [DOI: 10.1111/j.1399-3046.2005.00323.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
29 Roberts RJ, Wells AC, Unitt E, Griffiths M, Tasker AD, Allison ME, Bradley JA, Watson CJ. Sirolimus-induced pneumonitis following liver transplantation. Liver Transpl 2007;13:853-6. [DOI: 10.1002/lt.21141] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.5] [Reference Citation Analysis]
30 Pedroso SL, Martins LS, Sousa S, Reis A, Dias L, Henriques AC, Sarmento AM, Cabrita A. Pulmonary alveolar proteinosis ? a rare pulmonary toxicity of sirolimus. Transplant Int 2007;20:291-6. [DOI: 10.1111/j.1432-2277.2006.00408.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
31 Brouard S, Le Bars A, Dufay A, Gosselin M, Foucher Y, Guillet M, Cesbron-Gautier A, Thervet E, Legendre C, Dugast E, Pallier A, Guillot-Gueguen C, Lagoutte L, Evanno G, Giral M, Soulillou JP. Identification of a gene expression profile associated with operational tolerance among a selected group of stable kidney transplant patients. Transpl Int 2011;24:536-47. [PMID: 21457359 DOI: 10.1111/j.1432-2277.2011.01251.x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 3.8] [Reference Citation Analysis]
32 Solazzo A, Botta C, Nava F, Baisi A, Bonucchi D, Cappelli G. Interstitial Lung Disease After Kidney Transplantation and the Role of Everolimus. Transplant Proc 2016;48:349-51. [PMID: 27109953 DOI: 10.1016/j.transproceed.2015.12.039] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
33 Duran I, Siu LL, Oza AM, Chung TB, Sturgeon J, Townsley CA, Pond GR, Seymour L, Niroumand M. Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus. Eur J Cancer 2006;42:1875-80. [PMID: 16806903 DOI: 10.1016/j.ejca.2006.03.015] [Cited by in Crossref: 125] [Cited by in F6Publishing: 101] [Article Influence: 8.3] [Reference Citation Analysis]
34 Zaza G, Tomei P, Ria P, Granata S, Boschiero L, Lupo A. Systemic and nonrenal adverse effects occurring in renal transplant patients treated with mTOR inhibitors. Clin Dev Immunol. 2013;2013:403280. [PMID: 24151517 DOI: 10.1155/2013/403280] [Cited by in Crossref: 47] [Cited by in F6Publishing: 39] [Article Influence: 5.9] [Reference Citation Analysis]
35 Kasap B. Sirolimus in pediatric renal transplantation: Sirolimus in pediatric renal transplantation. Pediatric Transplantation 2011;15:673-85. [DOI: 10.1111/j.1399-3046.2011.01575.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
36 Martinet W, De Loof H, De Meyer GR. mTOR inhibition: a promising strategy for stabilization of atherosclerotic plaques. Atherosclerosis. 2014;233:601-607. [PMID: 24534455 DOI: 10.1016/j.atherosclerosis.2014.01.040] [Cited by in Crossref: 120] [Cited by in F6Publishing: 105] [Article Influence: 17.1] [Reference Citation Analysis]
37 Albiges L, Chamming's F, Duclos B, Stern M, Motzer RJ, Ravaud A, Camus P. Incidence and management of mTOR inhibitor-associated pneumonitis in patients with metastatic renal cell carcinoma. Ann Oncol 2012;23:1943-53. [PMID: 22689175 DOI: 10.1093/annonc/mds115] [Cited by in Crossref: 82] [Cited by in F6Publishing: 62] [Article Influence: 9.1] [Reference Citation Analysis]
38 Butani L. Investigation of Pediatric Renal Transplant Recipients with Heavy Proteinuria after Sirolimus Rescue. Transplantation 2004;78:1362-6. [DOI: 10.1097/01.tp.0000140868.88149.63] [Cited by in Crossref: 60] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
39 Molinari M, Berman K, Meeberg G, Shapiro JA, Bigam D, Trotter JF, Kneteman N. Multicentric outcome analysis of sirolimus-based immunosuppression in 252 liver transplant recipients. Transpl Int. 2010;23:155-168. [PMID: 19765266 DOI: 10.1111/j.1432-2277.2009.00969.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.0] [Reference Citation Analysis]
40 Jiménez-Rivera C, Avitzur Y, Fecteau AH, Jones N, Grant D, Ng VL. Sirolimus for pediatric liver transplant recipients with post-transplant lymphoproliferative disease and hepatoblastoma. Pediatr Transplant. 2004;8:243-248. [PMID: 15176961 DOI: 10.1111/j.1399-3046.2004.00156.x] [Cited by in Crossref: 59] [Cited by in F6Publishing: 47] [Article Influence: 3.5] [Reference Citation Analysis]
41 Knight RJ, Kerman RH, Zela S, Podder H, Van Buren CT, Katz S, Kahan BD. Thymoglobulin, sirolimus, and reduced-dose cyclosporine provides excellent rejection prophylaxis for pancreas transplantation: . Transplantation 2003;75:1301-6. [DOI: 10.1097/01.tp.0000061768.98058.ec] [Cited by in Crossref: 17] [Article Influence: 0.9] [Reference Citation Analysis]
42 Peddi PF, Shatsky RA, Hurvitz SA. Noninfectious pneumonitis with the use of mTOR inhibitors in breast cancer. Cancer Treatment Reviews 2014;40:320-6. [DOI: 10.1016/j.ctrv.2013.08.004] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 2.1] [Reference Citation Analysis]
43 Adibelli Z, Dilek M, Kocak B, Tülek N, Uzun O, Akpolat T. An unusual presentation of sirolimus associated cough in a renal transplant recipient. Transplant Proc 2007;39:3463-4. [PMID: 18089408 DOI: 10.1016/j.transproceed.2007.09.033] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
44 Fairbanks KD, Eustace JA, Fine D, Thuluvath PJ. Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus. Liver Transpl. 2003;9:1079-1085. [PMID: 14526403 DOI: 10.1053/jlts.2003.50183] [Cited by in Crossref: 106] [Cited by in F6Publishing: 93] [Article Influence: 6.2] [Reference Citation Analysis]
45 Atkinson BJ, Cauley DH, Ng C, Millikan RE, Xiao L, Corn P, Jonasch E, Tannir NM. Mammalian target of rapamycin (mTOR) inhibitor-associated non-infectious pneumonitis in patients with renal cell cancer: predictors, management, and outcomes. BJU Int 2014;113:376-82. [PMID: 24053120 DOI: 10.1111/bju.12420] [Cited by in Crossref: 39] [Cited by in F6Publishing: 30] [Article Influence: 4.9] [Reference Citation Analysis]
46 Marty FM, Lowry CM, Cutler CS, Campbell BJ, Fiumara K, Baden LR, Antin JH. Voriconazole and Sirolimus Coadministration after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation 2006;12:552-9. [DOI: 10.1016/j.bbmt.2005.12.032] [Cited by in Crossref: 84] [Cited by in F6Publishing: 56] [Article Influence: 5.6] [Reference Citation Analysis]
47 Granata S, Santoro G, Masola V, Tomei P, Sallustio F, Pontrelli P, Accetturo M, Antonucci N, Carratù P, Lupo A, Zaza G. In Vitro Identification of New Transcriptomic and miRNomic Profiles Associated with Pulmonary Fibrosis Induced by High Doses Everolimus: Looking for New Pathogenetic Markers and Therapeutic Targets. Int J Mol Sci 2018;19:E1250. [PMID: 29677166 DOI: 10.3390/ijms19041250] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
48 Hymes LC, Warshaw BL, Amaral SG, Greenbaum LA. Tacrolimus withdrawal and conversion to sirolimus at three months post-pediatric renal transplantation. Pediatr Transplant 2008;12:773-7. [PMID: 18282210 DOI: 10.1111/j.1399-3046.2008.00906.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
49 Gong C, Xiao Q, Li Y, Gu Y, Zhang J, Wang L, Cao J, Tao Z, Zhao Y, Xie Y, Hu X, Wang B. Everolimus-Related Pneumonitis in Patients with Metastatic Breast Cancer: Incidence, Radiographic Patterns, and Relevance to Clinical Outcome. Oncologist 2021;26:e580-7. [PMID: 33191524 DOI: 10.1002/onco.13594] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
50 Carter BW, Erasmus JJ. Acute Thoracic Findings in Oncologic Patients. Journal of Thoracic Imaging 2015;30:233-46. [DOI: 10.1097/rti.0000000000000148] [Cited by in Crossref: 16] [Cited by in F6Publishing: 2] [Article Influence: 2.7] [Reference Citation Analysis]
51 Sánchez-Fructuoso AI. Everolimus: an update on the mechanism of action, pharmacokinetics and recent clinical trials. Expert Opin Drug Metab Toxicol 2008;4:807-19. [PMID: 18611120 DOI: 10.1517/17425255.4.6.807] [Cited by in Crossref: 41] [Cited by in F6Publishing: 31] [Article Influence: 3.2] [Reference Citation Analysis]
52 Sharif S, Kong MW, Drakakis J, Cunha BA. Fever of unknown origin (FUO) in a renal transplant recipient due to drug fever from sirolimus. Infection 2016;44:559-61. [DOI: 10.1007/s15010-016-0877-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
53 Gupte GL, Mahadevan S, Clarke JR, Alton H, Beath SV. Sirolimus-related pulmonary toxicity mimicking 'asthma like' symptoms. World J Gastroenterol 2007;13:5151-3. [PMID: 17876884 DOI: 10.3748/wjg.v13.i38.5151] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
54 Collard HR, Schwarz MI. Diffuse alveolar hemorrhage. Clinics in Chest Medicine 2004;25:583-92. [DOI: 10.1016/j.ccm.2004.04.007] [Cited by in Crossref: 126] [Cited by in F6Publishing: 69] [Article Influence: 7.4] [Reference Citation Analysis]
55 White DA, Camus P, Endo M, Escudier B, Calvo E, Akaza H, Uemura H, Kpamegan E, Kay A, Robson M, Ravaud A, Motzer RJ. Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma. Am J Respir Crit Care Med 2010;182:396-403. [PMID: 20194812 DOI: 10.1164/rccm.200911-1720OC] [Cited by in Crossref: 153] [Cited by in F6Publishing: 49] [Article Influence: 13.9] [Reference Citation Analysis]
56 Zaza G, Granata S, Caletti C, Signorini L, Stallone G, Lupo A. mTOR Inhibition Role in Cellular Mechanisms. Transplantation 2018;102:S3-S16. [DOI: 10.1097/tp.0000000000001806] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 5.3] [Reference Citation Analysis]
57 Wang WL, Yu LX. Acute respiratory distress attributed to sirolimus in solid organ transplant recipients. The American Journal of Emergency Medicine 2015;33:124.e1-4. [DOI: 10.1016/j.ajem.2014.05.047] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
58 Sanchez EQ, Martin AP, Ikegami T, Uemura T, Narasimhan G, Goldstein RM, Levy MF, Chinnakotla S, Dawson S, Randall HB. Sirolimus conversion after liver transplantation: improvement in measured glomerular filtration rate after 2 years. Transplant Proc. 2005;37:4416-4423. [PMID: 16387135 DOI: 10.1016/j.transproceed.2005.10.019] [Cited by in Crossref: 47] [Cited by in F6Publishing: 36] [Article Influence: 3.1] [Reference Citation Analysis]
59 Tomei P, Masola V, Granata S, Bellin G, Carratù P, Ficial M, Ventura VA, Onisto M, Resta O, Gambaro G, Chilosi M, Lupo A, Zaza G. Everolimus-induced epithelial to mesenchymal transition (EMT) in bronchial/pulmonary cells: when the dosage does matter in transplantation. J Nephrol 2016;29:881-91. [PMID: 27026415 DOI: 10.1007/s40620-016-0295-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
60 Pellé G, Xu Y, Khoury N, Mougenot B, Rondeau E. Thrombotic microangiopathy in marginal kidneys after sirolimus use. Am J Kidney Dis 2005;46:1124-8. [PMID: 16310579 DOI: 10.1053/j.ajkd.2005.08.037] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
61 Elmariah H, Kasamon YL, Zahurak M, Macfarlane KW, Tucker N, Rosner GL, Bolaños-Meade J, Fuchs EJ, Wagner-Johnston N, Swinnen LJ, Huff CA, Matsui WH, Gladstone DE, McCurdy SR, Borrello I, Gocke CB, Shanbhag S, Cooke KR, Ali SA, Brodsky RA, DeZern AE, Luznik L, Jones RJ, Ambinder RF. Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide Using Non-First-Degree Related Donors. Biol Blood Marrow Transplant 2018;24:1099-102. [PMID: 29452245 DOI: 10.1016/j.bbmt.2018.02.005] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 10.3] [Reference Citation Analysis]
62 Schlesinger C, Koss MN. The organizing pneumonias: an update and review: . Current Opinion in Pulmonary Medicine 2005;11:422-30. [DOI: 10.1097/01.mcp.0000175521.41729.07] [Cited by in Crossref: 56] [Cited by in F6Publishing: 34] [Article Influence: 3.5] [Reference Citation Analysis]
63 Bukowski RM. Temsirolimus: a safety and efficacy review. Expert Opin Drug Saf 2012;11:861-79. [PMID: 22861825 DOI: 10.1517/14740338.2012.713344] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
64 Costabel U, Uzaslan E, Guzman J. Bronchoalveolar lavage in drug-induced lung disease. Clinics in Chest Medicine 2004;25:25-35. [DOI: 10.1016/s0272-5231(03)00143-6] [Cited by in Crossref: 67] [Cited by in F6Publishing: 15] [Article Influence: 3.9] [Reference Citation Analysis]
65 Hymes LC, Warshaw BL. Sirolimus in pediatric patients: Results in the first 6 months post-renal transplant. Pediatric Transplantation 2005;9:520-2. [DOI: 10.1111/j.1399-3046.2005.00324.x] [Cited by in Crossref: 50] [Cited by in F6Publishing: 37] [Article Influence: 3.1] [Reference Citation Analysis]
66 Chhajed PN, Dickenmann M, Bubendorf L, Mayr M, Steiger J, Tamm M. Patterns of pulmonary complications associated with sirolimus. Respiration 2006;73:367-74. [PMID: 16127266 DOI: 10.1159/000087945] [Cited by in Crossref: 57] [Cited by in F6Publishing: 42] [Article Influence: 3.6] [Reference Citation Analysis]
67 Caetano Mota P, Vaz AP, Castro Ferreira I, Bustorff M, Damas C. Lung and renal transplantation. Rev Port Pneumol 2009;15:1073-99. [PMID: 19859628 DOI: 10.1016/s2173-5115(09)70169-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
68 Rodríguez-Moreno A, Ridao N, García-Ledesma P, Calvo N, Pérez-Flores I, Marques M, Barrientos A, Sánchez-Fructuoso AI. Sirolimus and everolimus induced pneumonitis in adult renal allograft recipients: experience in a center. Transplant Proc 2009;41:2163-5. [PMID: 19715862 DOI: 10.1016/j.transproceed.2009.06.003] [Cited by in Crossref: 36] [Cited by in F6Publishing: 27] [Article Influence: 3.3] [Reference Citation Analysis]
69 Ussavarungsi K, Elsanjak A, Laski M, Raj R, Nugent K. Sirolimus induced granulomatous interstitial pneumonitis. Respir Med Case Rep 2012;7:8-11. [PMID: 26029599 DOI: 10.1016/j.rmcr.2012.09.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
70 Schrader J, Sterneck M, Klose H, Lohse AW, Nashan B, Fischer L. Everolimus-induced pneumonitis: report of the first case in a liver transplant recipient and review of treatment options. Transpl Int. 2010;23:110-113. [PMID: 19497063 DOI: 10.1111/j.1432-2277.2009.00900.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
71 Zhu J, Liu H, Cui H, Tang Z, Song C, Zhang R. Safety and efficacy of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent. J Mater Sci Mater Med 2017;28:54. [PMID: 28197826 DOI: 10.1007/s10856-017-5864-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
72 Willemsen AE, Grutters JC, Gerritsen WR, van Erp NP, van Herpen CM, Tol J. mTOR inhibitor-induced interstitial lung disease in cancer patients: Comprehensive review and a practical management algorithm: mTOR inhibitor-induced ILD in cancer patients. Int J Cancer 2016;138:2312-21. [DOI: 10.1002/ijc.29887] [Cited by in Crossref: 53] [Cited by in F6Publishing: 35] [Article Influence: 8.8] [Reference Citation Analysis]
73 Willemsen AECAB, He X, van Cranenbroek B, de Jong PC, de Boer M, Joosten I, Koenen HJPM, van Herpen CML, Gerritsen WR. Baseline effector cells predict response and NKT cells predict pulmonary toxicity in advanced breast cancer patients treated with everolimus and exemestane. Int Immunopharmacol 2021;93:107404. [PMID: 33524804 DOI: 10.1016/j.intimp.2021.107404] [Reference Citation Analysis]
74 White DA, Schwartz LH, Dimitrijevic S, Scala LD, Hayes W, Gross SH. Characterization of Pneumonitis in Patients with Advanced Non-small Cell Lung Cancer Treated with Everolimus (RAD001). Journal of Thoracic Oncology 2009;4:1357-63. [DOI: 10.1097/jto.0b013e3181ba20b1] [Cited by in Crossref: 37] [Cited by in F6Publishing: 9] [Article Influence: 3.1] [Reference Citation Analysis]
75 Zhang X, Ran Y, Wang K. Risk of mTOR inhibitors induced severe pneumonitis in cancer patients: a meta-analysis of randomized controlled trials. Future Oncology 2016;12:1529-39. [DOI: 10.2217/fon-2016-0020] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
76 Hadoux J, Vignot S, De La Motte Rouge T. Renal cell carcinoma: focus on safety and efficacy of temsirolimus. Clin Med Insights Oncol 2010;4:143-54. [PMID: 21234295 DOI: 10.4137/CMO.S4482] [Cited by in Crossref: 31] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
77 Bitzan M, Ouahed JD, Carpineta L, Bernard C, Bell LE. Cryptogenic organizing pneumonia after rituximab therapy for presumed post-kidney transplant lymphoproliferative disease. Pediatr Nephrol 2010;25:1163-7. [PMID: 20140460 DOI: 10.1007/s00467-010-1447-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
78 Davidson KR, Ha DM, Schwarz MI, Chan ED. Bronchoalveolar lavage as a diagnostic procedure: a review of known cellular and molecular findings in various lung diseases. J Thorac Dis 2020;12:4991-5019. [PMID: 33145073 DOI: 10.21037/jtd-20-651] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
79 Neff GW, Montalbano M, Tzakis AG. Ten years of sirolimus therapy in orthotopic liver transplant recipients. Transplant Proc. 2003;35:209S-216S. [PMID: 12742498 DOI: 10.1016/s0041-1345(03)00217-3] [Cited by in Crossref: 53] [Cited by in F6Publishing: 9] [Article Influence: 2.9] [Reference Citation Analysis]
80 Soefje SA, Karnad A, Brenner AJ. Common toxicities of mammalian target of rapamycin inhibitors. Target Oncol 2011;6:125-9. [PMID: 21499766 DOI: 10.1007/s11523-011-0174-9] [Cited by in Crossref: 80] [Cited by in F6Publishing: 63] [Article Influence: 8.0] [Reference Citation Analysis]
81 Watson CJ, Bradley JA. Sirolimus and everolimus: inhibitors of mammalian target of rapamycin in liver transplantation. Transplantation Reviews 2006;20:104-14. [DOI: 10.1016/j.trre.2006.06.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
82 Paris A, Goupil F, Kernaonet E, Foulet-Rogé A, Molinier O, Gagnadoux F, Lebas FX. [Drug-induced pneumonitis due to sirolimus: an interaction with atorvastatin?]. Rev Mal Respir 2012;29:64-9. [PMID: 22240222 DOI: 10.1016/j.rmr.2010.03.026] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
83 Penttilä P, Donskov F, Rautiola J, Peltola K, Laukka M, Bono P. Everolimus-induced pneumonitis associates with favourable outcome in patients with metastatic renal cell carcinoma. European Journal of Cancer 2017;81:9-16. [DOI: 10.1016/j.ejca.2017.05.004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
84 Patel SJ, Elliott EN, Knight RJ, Gaber LW, Gaber AO. Considerations in sirolimus use in the early and late post-transplant periods. Expert Opinion on Drug Safety 2009;8:421-34. [DOI: 10.1517/14740330903037156] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
85 Lisik W, Kahan BD. Proliferation signal inhibitors: chemical, biologic, and clinical properties. Transplantation Reviews 2005;19:186-212. [DOI: 10.1016/j.trre.2005.11.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
86 Mcwilliams TJ, Levvey BJ, Russell PA, Milne DG, Snell GI. Interstitial pneumonitis associated with sirolimus: a dilemma for lung transplantation. The Journal of Heart and Lung Transplantation 2003;22:210-3. [DOI: 10.1016/s1053-2498(02)00564-8] [Cited by in Crossref: 53] [Cited by in F6Publishing: 8] [Article Influence: 2.9] [Reference Citation Analysis]
87 Cherri S, Noventa S, Fanelli M, Calandra G, Prochilo T, Bnà C, Savelli G, Zaniboni A. Drug-Related Pneumonitis in Cancer Treatment during the COVID-19 Era. Cancers (Basel) 2021;13:1052. [PMID: 33801385 DOI: 10.3390/cancers13051052] [Reference Citation Analysis]
88 Dorschner L, Speich R, Ruschitzka F, Seebach JD, Gallino A. Everolimus-induced drug fever after heart transplantation. Transplantation. 2004;78:303-304. [PMID: 15280699 DOI: 10.1097/01.TP.0000135116.17451.CB] [Cited by in Crossref: 8] [Article Influence: 0.5] [Reference Citation Analysis]
89 Ravaud A, Schmidinger M. Clinical biomarkers of response in advanced renal cell carcinoma. Ann Oncol 2013;24:2935-42. [PMID: 23925998 DOI: 10.1093/annonc/mdt288] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 4.8] [Reference Citation Analysis]
90 Israel-biet D, Danel C. Contribution du lavage bronchoalvéolaire à la prise en charge des pneumopathies interstitielles diffuses. Revue de Pneumologie Clinique 2005;61:141-8. [DOI: 10.1016/s0761-8417(05)84805-9] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
91 Dabydeen DA, Jagannathan JP, Ramaiya N, Krajewski K, Schutz FA, Cho DC, Pedrosa I, Choueiri TK. Pneumonitis associated with mTOR inhibitors therapy in patients with metastatic renal cell carcinoma: incidence, radiographic findings and correlation with clinical outcome. Eur J Cancer 2012;48:1519-24. [PMID: 22483544 DOI: 10.1016/j.ejca.2012.03.012] [Cited by in Crossref: 69] [Cited by in F6Publishing: 57] [Article Influence: 7.7] [Reference Citation Analysis]
92 Masola V, Carraro A, Zaza G, Bellin G, Montin U, Violi P, Lupo A, Tedeschi U. Epithelial to mesenchymal transition in the liver field: the double face of Everolimus in vitro. BMC Gastroenterol 2015;15:118. [PMID: 26369804 DOI: 10.1186/s12876-015-0347-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
93 Boers-doets CB, Raber-durlacher JE, Treister NS, Epstein JB, Arends AB, Wiersma DR, Lalla RV, Logan RM, van Erp NP, Gelderblom H. Mammalian target of rapamycin inhibitor-associated stomatitis. Future Oncology 2013;9:1883-92. [DOI: 10.2217/fon.13.141] [Cited by in Crossref: 53] [Cited by in F6Publishing: 40] [Article Influence: 6.6] [Reference Citation Analysis]
94 Elmariah H, Fuchs EJ. Post-transplantation cyclophosphamide to facilitate HLA-haploidentical hematopoietic cell transplantation: Mechanisms and results. Seminars in Hematology 2019;56:183-9. [DOI: 10.1053/j.seminhematol.2018.09.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
95 Kotloff RM, Ahya VN, Crawford SW. Pulmonary complications of solid organ and hematopoietic stem cell transplantation. Am J Respir Crit Care Med. 2004;170:22-48. [PMID: 15070821 DOI: 10.1164/rccm.200309-1322so] [Cited by in Crossref: 263] [Cited by in F6Publishing: 52] [Article Influence: 15.5] [Reference Citation Analysis]
96 Wang X, Pan C, Gong J, Liu X, Li H. Enhancing the Enrichment of Pharmacophore-Based Target Prediction for the Polypharmacological Profiles of Drugs. J Chem Inf Model 2016;56:1175-83. [PMID: 27187084 DOI: 10.1021/acs.jcim.5b00690] [Cited by in Crossref: 68] [Cited by in F6Publishing: 49] [Article Influence: 13.6] [Reference Citation Analysis]
97 Bauer C, Lidove O, Lamotte C, Petit T, Lieberherr D, Chauveheid M, Legendre C, Crestani B, Dombret M, Laissy J, Antoine C, Pegaz-fiornet B, Papo T. Pneumopathie organisée au sirolimus : un diagnostic à évoquer chez le patient transplanté d'organe. La Revue de Médecine Interne 2006;27:248-52. [DOI: 10.1016/j.revmed.2005.11.014] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
98 Pallet N, Legendre C. Adverse events associated with mTOR inhibitors. Expert Opin Drug Saf. 2013;12:177-186. [PMID: 23252795 DOI: 10.1517/14740338.2013.752814] [Cited by in Crossref: 117] [Cited by in F6Publishing: 104] [Article Influence: 13.0] [Reference Citation Analysis]
99 Ng VC, Johnson JJ, Cuellar S. Targeting the mammalian target of rapamycin pathway with everolimus: implications for the management of metastatic breast cancer. J Oncol Pharm Pract 2015;21:433-42. [PMID: 24964967 DOI: 10.1177/1078155214540732] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
100 Willemsen AECAB, Tol J, van Erp NP, Jonker MA, de Boer M, Meek B, de Jong PC, van Moorsel C, Gerritsen WR, Grutters JC, van Herpen CML. Prospective Study of Drug-induced Interstitial Lung Disease in Advanced Breast Cancer Patients Receiving Everolimus Plus Exemestane. Target Oncol 2019;14:441-51. [PMID: 31325105 DOI: 10.1007/s11523-019-00656-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
101 Martín-penagos L, Rodrigo E, Ruíz J, Agüero J, Fernandez-mazarrasa C, Martínez L, Piñera C, Arias M. Lung cavitation due to Mycobacterium xenopi in a renal transplant recipient. Transplant Infectious Disease 2009;11:249-52. [DOI: 10.1111/j.1399-3062.2009.00376.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
102 Kim EY, Kim A, Kim SK, Kim HJ, Chang J, Ahn CM, Chang YS. Inhibition of mTORC1 induces loss of E-cadherin through AKT/GSK-3β signaling-mediated upregulation of E-cadherin repressor complexes in non-small cell lung cancer cells. Respir Res 2014;15:26. [PMID: 24571487 DOI: 10.1186/1465-9921-15-26] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.1] [Reference Citation Analysis]
103 Ruemmele FM, Jan D, Lacaille F, Cézard JP, Canioni D, Phillips AD, Peuchmaur M, Aigrain Y, Brousse N, Schmitz J, Revillon Y, Goulet O. New perspectives for children with microvillous inclusion disease: early small bowel transplantation. Transplantation 2004;77:1024-8. [PMID: 15087765 DOI: 10.1097/01.tp.0000119163.30745.c1] [Cited by in Crossref: 54] [Cited by in F6Publishing: 10] [Article Influence: 3.2] [Reference Citation Analysis]
104 Buhaescu I, Izzedine H, Covic A. Sirolimus--challenging current perspectives. Ther Drug Monit 2006;28:577-84. [PMID: 17038868 DOI: 10.1097/01.ftd.0000245377.93401.39] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 2.6] [Reference Citation Analysis]
105 Morath C, Schwenger V, Ksoll-Rudek D, Sommerer C, Beimler J, Schmidt J, Zeier M. Four cases of sirolimus-associated interstitial pneumonitis: identification of risk factors. Transplant Proc. 2007;39:99-102. [PMID: 17275483 DOI: 10.1016/j.transproceed.2006.10.219] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
106 Camus P, Rosenow EC 3rd. Iatrogenic lung disease. Clin Chest Med 2004;25:XIII-XIX. [PMID: 15062613 DOI: 10.1016/S0272-5231(03)00146-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
107 Vlahakis NE, Rickman OB, Morgenthaler T. Sirolimus-associated diffuse alveolar hemorrhage. Mayo Clin Proc 2004;79:541-5. [PMID: 15065619 DOI: 10.4065/79.4.541] [Cited by in Crossref: 52] [Cited by in F6Publishing: 39] [Article Influence: 3.1] [Reference Citation Analysis]
108 Veroux M, Tallarita T, Corona D, D’assoro A, Gurrieri C, Veroux P. Sirolimus in solid organ transplantation: current therapies and new frontiers. Immunotherapy 2011;3:1487-97. [DOI: 10.2217/imt.11.143] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
109 Doi A, Fujimoto A, Sato S, Uno T, Kanda Y, Asami K, Tanaka Y, Kita A, Satoh R, Sugiura R. Chemical genomics approach to identify genes associated with sensitivity to rapamycin in the fission yeast Schizosaccharomyces pombe. Genes Cells 2015;20:292-309. [DOI: 10.1111/gtc.12223] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
110 Kelchtermans J, Chang J, Glaberson W, DeFreitas M, Alba-Sandoval M, Chandar J. A Pediatric Case of Sirolimus-Associated Pneumonitis After Kidney Transplantation. J Pediatr Pharmacol Ther 2020;25:459-64. [PMID: 32641918 DOI: 10.5863/1551-6776-25.5.459] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
111 Sola E, Lopez V, Burgos D, Cabello M, Gutierrez C, Martin A, Peña M, Gonzalez-Molina M. Pulmonary toxicity associated with sirolimus treatment in kidney transplantation. Transplant Proc 2006;38:2438-40. [PMID: 17097960 DOI: 10.1016/j.transproceed.2006.08.037] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
112 Brar JS, Ambreen Q, James S. Sirolimus induced Interstitial Pneumonitis and Diffuse Alveolar Hemorrhage. Chest 2004;126:971S. [DOI: 10.1378/chest.126.4_meetingabstracts.971s] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
113 Kirby S, Satoskar A, Brodsky S, Pope-Harman A, Nunley D, Hitchcock C, Pelletier R, Ross P, Nadasdy T, Shilo K. Histological spectrum of pulmonary manifestations in kidney transplant recipients on sirolimus inclusive immunosuppressive regimens. Diagn Pathol 2012;7:25. [PMID: 22416975 DOI: 10.1186/1746-1596-7-25] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
114 Ensor CR, Doligalski CT. Proliferation signal inhibitor toxicities after thoracic transplantation. Expert Opinion on Drug Metabolism & Toxicology 2012;9:63-77. [DOI: 10.1517/17425255.2012.726219] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
115 Shorr AF, Susla GM, O'grady NP. Pulmonary Infiltrates in the Non-HIV-Infected Immunocompromised Patient. Chest 2004;125:260-71. [DOI: 10.1378/chest.125.1.260] [Cited by in Crossref: 76] [Cited by in F6Publishing: 58] [Article Influence: 4.5] [Reference Citation Analysis]
116 Chinnakotla S, Klintmalm GB. Induction and Maintenance of Immunosuppression. Transplantation of the Liver. Elsevier; 2005. pp. 1213-34. [DOI: 10.1016/b978-0-7216-0118-2.50080-x] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
117 Lehmann R, Weber M, Berthold P, Züllig R, Pfammatter T, Moritz W, Mädler K, Donath M, Ambühl P, Demartines N, Clavien And PA, Andreia Spinas G. Successful simultaneous islet-kidney transplantation using a steroid-free immunosuppression: two-year follow-up. Am J Transplant 2004;4:1117-23. [PMID: 15196070 DOI: 10.1111/j.1600-6143.2004.00468.x] [Cited by in Crossref: 47] [Cited by in F6Publishing: 31] [Article Influence: 2.9] [Reference Citation Analysis]
118 Thervet E, Martinez F, Legendre C. Benefit-Risk Assessment of Ciclosporin Withdrawal in Renal Transplant Recipients: . Drug Safety 2004;27:457-76. [DOI: 10.2165/00002018-200427070-00003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
119 Tsai M, Lee C, Hu R, Lee P. Conversion to Combined Therapy with Sirolimus and Mycophenolate Mofetil Improved Renal Function in Stable Renal Transplant Recipients. Journal of the Formosan Medical Association 2007;106:372-9. [DOI: 10.1016/s0929-6646(09)60322-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
120 Patel AV, Hahn T, Bogner PN, Loud PA, Brown K, Paplham P, Syta M, Battiwalla M, McCarthy PL. Fatal diffuse alveolar hemorrhage associated with sirolimus after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2010;45:1363-4. [PMID: 19966843 DOI: 10.1038/bmt.2009.339] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
121 Kahan B. Toxicity spectrum of inhibitors of mammalian target of rapamycin in organ transplantation: etiology, pathogenesis and treatment. Expert Opinion on Drug Safety 2011;10:727-49. [DOI: 10.1517/14740338.2011.579898] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
122 Nozawa M, Ohzeki T, Tamada S, Hongo F, Anai S, Fujimoto K, Miki T, Nakatani T, Fukasawa S, Uemura H. Differences in adverse event profiles between everolimus and temsirolimus and the risk factors for non-infectious pneumonitis in advanced renal cell carcinoma. Int J Clin Oncol 2015;20:790-5. [DOI: 10.1007/s10147-014-0764-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
123 Mita MM, Mita AC, Chu QS, Rowinsky EK, Fetterly GJ, Goldston M, Patnaik A, Mathews L, Ricart AD, Mays T, Knowles H, Rivera VM, Kreisberg J, Bedrosian CL, Tolcher AW. Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies. J Clin Oncol 2008;26:361-7. [PMID: 18202410 DOI: 10.1200/JCO.2007.12.0345] [Cited by in Crossref: 219] [Cited by in F6Publishing: 84] [Article Influence: 16.8] [Reference Citation Analysis]
124 Lee HS, Huh KH, Kim YS, Kim MS, Kim HJ, Kim SI, Joo DJ. Sirolimus-induced pneumonitis after renal transplantation: a single-center experience. Transplant Proc 2012;44:161-3. [PMID: 22310604 DOI: 10.1016/j.transproceed.2011.11.059] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 2.2] [Reference Citation Analysis]
125 Dantal J. Everolimus: preventing organ rejection in adult kidney transplant recipients. Expert Opinion on Pharmacotherapy 2012;13:767-78. [DOI: 10.1517/14656566.2012.662955] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
126 Rodriguez-Cubillo B, de la Higuera MAM, Lucena R, Franci EV, Hurtado M, Romero NC, Moreno AR, Valencia D, Velo M, Fornie IS, Sanchez-Fructuoso AI. Should cyclosporine be useful in renal transplant recipients affected by SARS-CoV-2? Am J Transplant 2020;20:3173-81. [PMID: 32529737 DOI: 10.1111/ajt.16141] [Cited by in Crossref: 33] [Cited by in F6Publishing: 25] [Article Influence: 33.0] [Reference Citation Analysis]
127 Barr PM, Saylors GB, Spurgeon SE, Cheson BD, Greenwald DR, O'Brien SM, Liem AK, Mclntyre RE, Joshi A, Abella-Dominicis E, Hawkins MJ, Reddy A, Di Paolo J, Lee H, He J, Hu J, Dreiling LK, Friedberg JW. Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL. Blood 2016;127:2411-5. [PMID: 26968534 DOI: 10.1182/blood-2015-12-683516] [Cited by in Crossref: 94] [Cited by in F6Publishing: 84] [Article Influence: 18.8] [Reference Citation Analysis]
128 Fine NM, Kushwaha SS. Recent Advances in Mammalian Target of Rapamycin Inhibitor Use in Heart and Lung Transplantation. Transplantation 2016;100:2558-68. [DOI: 10.1097/tp.0000000000001432] [Cited by in Crossref: 32] [Cited by in F6Publishing: 7] [Article Influence: 6.4] [Reference Citation Analysis]
129 Rabe C, Appenrodt B, Hoff C, Ewig S, Klehr HU, Sauerbruch T, Nickenig G, Tasci S. Severe respiratory failure due to diffuse alveolar hemorrhage: clinical characteristics and outcome of intensive care. J Crit Care 2010;25:230-5. [PMID: 19592204 DOI: 10.1016/j.jcrc.2009.04.009] [Cited by in Crossref: 27] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
130 Grellety T, Brugères-chakiba C, Chaminade A, Roubaud G, Ravaud A, Gross-goupil M. Révision de l’index thérapeutique des thérapies ciblées dans le cancer du rein : le mieux peut-il être l’ennemi du bien ? La toxicité peut-elle prédire l’efficacité ? Bulletin du Cancer 2014;101:608-18. [DOI: 10.1684/bdc.2014.1935] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
131 Ivanyi P, Fuehner T, Adam M, Eichelberg C, Herrmann E, Merseburger AS, Ganser A, Grünwald V. Interstitial lung disease during targeted therapy in metastatic renal cell carcinoma: a case series from three centres. Med Oncol 2014;31:147. [PMID: 25134914 DOI: 10.1007/s12032-014-0147-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.1] [Reference Citation Analysis]
132 Tsukamoto T, Shinohara N, Tsuchiya N, Hamamoto Y, Maruoka M, Fujimoto H, Niwakawa M, Uemura H, Usami M, Terai A, Kanayama HO, Sumiyoshi Y, Eto M, Akaza H. Phase III trial of everolimus in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from RECORD-1. Jpn J Clin Oncol 2011;41:17-24. [PMID: 20965941 DOI: 10.1093/jjco/hyq166] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 3.5] [Reference Citation Analysis]
133 Alvarez RH, Bechara RI, Naughton MJ, Adachi JA, Reuben JM. Emerging Perspectives on mTOR Inhibitor-Associated Pneumonitis in Breast Cancer. Oncologist 2018;23:660-9. [PMID: 29487226 DOI: 10.1634/theoncologist.2017-0343] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
134 Avitzur Y, Jimenez-rivera C, Fecteau A, Jones N, Ngan BY, Ng VL. Interstitial Granulomatous Pneumonitis associated with Sirolimus in a Child after Liver Transplantation: . Journal of Pediatric Gastroenterology and Nutrition 2003;37:91-4. [DOI: 10.1097/00005176-200307000-00017] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.1] [Reference Citation Analysis]
135 Howard L, Gopalan D, Griffiths M, Mahadeva R. Sirolimus-Induced Pulmonary Hypersensitivity Associated With a CD4 T-Cell Infiltrate. Chest 2006;129:1718-21. [DOI: 10.1378/chest.129.6.1718] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 2.1] [Reference Citation Analysis]
136 Das BB, Shoemaker L, Subramanian S, Johnsrude C, Recto M, Austin EH. Acute sirolimus pulmonary toxicity in an infant heart transplant recipient: case report and literature review. J Heart Lung Transplant. 2007;26:296-298. [PMID: 17346635 DOI: 10.1016/j.healun.2006.12.004] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
137 Cravedi P, Ruggenenti P, Remuzzi G. Sirolimus for calcineurin inhibitors in organ transplantation: contra. Kidney International 2010;78:1068-74. [DOI: 10.1038/ki.2010.268] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 3.4] [Reference Citation Analysis]
138 Li L, Mok H, Jhaveri P, Bonnen MD, Sikora AG, Eissa NT, Komaki RU, Ghebre YT. Anticancer therapy and lung injury: molecular mechanisms. Expert Rev Anticancer Ther 2018;18:1041-57. [PMID: 29996062 DOI: 10.1080/14737140.2018.1500180] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
139 Ji Y, Chen S, Xiang B, Li K, Xu Z, Yao W, Lu G, Liu X, Xia C, Wang Q, Li Y, Wang C, Yang K, Yang G, Tang X, Xu T, Wu H. Sirolimus for the treatment of progressive kaposiform hemangioendothelioma: A multicenter retrospective study. Int J Cancer 2017;141:848-55. [PMID: 28486787 DOI: 10.1002/ijc.30775] [Cited by in Crossref: 57] [Cited by in F6Publishing: 41] [Article Influence: 14.3] [Reference Citation Analysis]
140 Sarkaria JN, Schwingler P, Schild SE, Grogan PT, Mladek AC, Mandrekar SJ, Tan AD, Kobayashi T, Marks RS, Kita H, Miller RC, Limper AH, Leof EB. Phase I trial of sirolimus combined with radiation and cisplatin in non-small cell lung cancer. J Thorac Oncol 2007;2:751-7. [PMID: 17762343 DOI: 10.1097/JTO.0b013e3180cc2587] [Cited by in Crossref: 32] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
141 Nguyen LS, Vautier M, Allenbach Y, Zahr N, Benveniste O, Funck-Brentano C, Salem JE. Sirolimus and mTOR Inhibitors: A Review of Side Effects and Specific Management in Solid Organ Transplantation. Drug Saf. 2019;42:813-825. [PMID: 30868436 DOI: 10.1007/s40264-019-00810-9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 24] [Article Influence: 18.0] [Reference Citation Analysis]
142 Baron D, Giral M, Brouard S. Reconsidering the detection of tolerance to individualize immunosuppression minimization and to improve long-term kidney graft outcomes. Transpl Int 2015;28:938-59. [DOI: 10.1111/tri.12578] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
143 Kotloff RM. Noninfectious Pulmonary Complications of Liver, Heart, and Kidney Transplantation. Clinics in Chest Medicine 2005;26:623-9. [DOI: 10.1016/j.ccm.2005.06.011] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
144 Zaza G, Granata S, Tomei P, Masola V, Gambaro G, Lupo A. mTOR inhibitors and renal allograft: Yin and Yang. J Nephrol 2014;27:495-506. [PMID: 24804854 DOI: 10.1007/s40620-014-0103-y] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
145 Baas MC, Struijk GH, Moes DJ, van den Berk IA, Jonkers RE, de Fijter JW, van der Heide JJ, van Dijk M, ten Berge IJ, Bemelman FJ. Interstitial pneumonitis caused by everolimus: a case-cohort study in renal transplant recipients. Transpl Int 2014;27:428-36. [PMID: 24484452 DOI: 10.1111/tri.12275] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
146 Iacovelli R, Palazzo A, Mezi S, Morano F, Naso G, Cortesi E. Incidence and risk of pulmonary toxicity in patients treated with mTOR inhibitors for malignancy. A meta-analysis of published trials. Acta Oncol 2012;51:873-9. [PMID: 22909392 DOI: 10.3109/0284186X.2012.705019] [Cited by in Crossref: 47] [Cited by in F6Publishing: 18] [Article Influence: 5.2] [Reference Citation Analysis]
147 Zhang Y, Yan H, Xu Z, Yang B, Luo P, He Q. Molecular basis for class side effects associated with PI3K/AKT/mTOR pathway inhibitors. Expert Opin Drug Metab Toxicol. 2019;15:767-774. [PMID: 31478386 DOI: 10.1080/17425255.2019.1663169] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 8.5] [Reference Citation Analysis]
148 Diekmann F, Budde K, Oppenheimer F, Fritsche L, Neumayer HH, Campistol JM. Predictors of Success in Conversion from Calcineurin Inhibitor to Sirolimus in Chronic Allograft Dysfunction. Am J Transplant 2004;4:1869-75. [DOI: 10.1111/j.1600-6143.2004.00590.x] [Cited by in Crossref: 204] [Cited by in F6Publishing: 165] [Article Influence: 12.0] [Reference Citation Analysis]
149 Thaunat O, Morelon E, Stern M, Buffet P, Offredo C, Mamzer-bruneel M, Kreis H. Mycobacterium xenopi pulmonary infection in two renal transplant recipients under sirolimus therapy. Transplant Infect Dis 2004;6:179-82. [DOI: 10.1111/j.1399-3062.2004.00071.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
150 Almeida F, Amorim S, Sarmento A, Santos L. Life-Threatening Everolimus-Associated Pneumonitis: A Case Report and a Review of the Literature. Transplant Proc 2018;50:933-8. [PMID: 29588066 DOI: 10.1016/j.transproceed.2017.12.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
151 Bertolini L, Vaglio A, Bignardi L, Buzio C, De Filippo M, Palmisano A, Mercati K, Zompatori M, Maggiore U. Subclinical interstitial lung abnormalities in stable renal allograft recipients in the era of modern immunosuppression. Transplant Proc 2011;43:2617-23. [PMID: 21911134 DOI: 10.1016/j.transproceed.2011.06.033] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 0.2] [Reference Citation Analysis]
152 Sankhala K, Mita A, Kelly K, Mahalingam D, Giles F, Mita M. The emerging safety profile of mTOR inhibitors, a novel class of anticancer agents. Target Oncol 2009;4:135-42. [PMID: 19381454 DOI: 10.1007/s11523-009-0107-z] [Cited by in Crossref: 68] [Cited by in F6Publishing: 62] [Article Influence: 5.7] [Reference Citation Analysis]
153 Shrestha NK, Mossad SB, Braun W. Pneumonitis associated with the use of mycophenolate mofetil. Transplantation 2003;75:1762. [DOI: 10.1097/01.tp.0000063932.68103.b5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
154 Garrod AS, Goyal RK, Weiner DJ. Sirolimus-induced interstitial lung disease following pediatric stem cell transplantation. Pediatr Transplant 2015;19:E75-7. [PMID: 25684631 DOI: 10.1111/petr.12438] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
155 Borders EB, Bivona C, Medina PJ. Mammalian target of rapamycin: biological function and target for novel anticancer agents. Am J Health Syst Pharm. 2010;67:2095-2106. [PMID: 21116000 DOI: 10.2146/ajhp100020] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 4.2] [Reference Citation Analysis]
156 Morelon E, Kreis H. Sirolimus therapy without calcineurin inhibitors: Necker Hospital 8-year experience. Transplantation Proceedings 2003;35:S52-7. [DOI: 10.1016/s0041-1345(03)00244-6] [Cited by in Crossref: 85] [Cited by in F6Publishing: 9] [Article Influence: 4.7] [Reference Citation Analysis]
157 Masola V, Zaza G, Granata S, Gambaro G, Onisto M, Lupo A. Everolimus-induced epithelial to mesenchymal transition in immortalized human renal proximal tubular epithelial cells: key role of heparanase. J Transl Med 2013;11:292. [PMID: 24256696 DOI: 10.1186/1479-5876-11-292] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
158 Sadowski K, Kotulska K, Jóźwiak S. Management of side effects of mTOR inhibitors in tuberous sclerosis patients.Pharmacol Rep. 2016;68:536-542. [PMID: 26891243 DOI: 10.1016/j.pharep.2016.01.005] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 6.4] [Reference Citation Analysis]
159 Stenton SB, Partovi N, Ensom MH. Sirolimus: the evidence for clinical pharmacokinetic monitoring. Clin Pharmacokinet. 2005;44:769-786. [PMID: 16029064 DOI: 10.2165/00003088-200544080-00001] [Cited by in Crossref: 75] [Cited by in F6Publishing: 59] [Article Influence: 5.0] [Reference Citation Analysis]
160 Colantonio DA, Borden KK, Clarke W. Comparison of the CEDIA® and MEIA® assays for the measurement of sirolimus in organ transplant recipients. Clinical Biochemistry 2007;40:680-7. [DOI: 10.1016/j.clinbiochem.2007.02.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
161 Bouvier G, Cellerin L, Henry B, Germaud P, Hourmant M, Sagan C, Magnan A. Everolimus associated interstitial pneumonitis: 3 Case reports. Respiratory Medicine CME 2009;2:181-4. [DOI: 10.1016/j.rmedc.2009.01.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
162 Barone GW, Gurley BJ, Abul-ezz SR, Gökden N. Sirolimus-induced thrombotic microangiopathy in a renal transplant recipient. American Journal of Kidney Diseases 2003;42:202-6. [DOI: 10.1016/s0272-6386(03)00424-4] [Cited by in Crossref: 50] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
163 Khalife WI, Kogoj P, Kar B. Sirolimus-induced Alveolar Hemorrhage. The Journal of Heart and Lung Transplantation 2007;26:652-7. [DOI: 10.1016/j.healun.2007.02.010] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
164 Gartrell BA, Ying J, Sivendran S, Boucher KM, Choueiri TK, Sonpavde G, Oh WK, Agarwal N, Galsky MD. Pulmonary complications with the use of mTOR inhibitors in targeted cancer therapy: a systematic review and meta-analysis. Target Oncol 2014;9:195-204. [PMID: 23852656 DOI: 10.1007/s11523-013-0289-2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
165 Tracey C, Hawley C, Griffin AD, Strutton G, Lynch S. Generalized, pruritic, ulcerating maculopapular rash necessitating cessation of sirolimus in a liver transplantation patient. Liver Transpl 2005;11:987-9. [DOI: 10.1002/lt.20499] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
166 Derosa L, Melenotte C, Griscelli F, Gachot B, Marabelle A, Kroemer G, Zitvogel L. The immuno-oncological challenge of COVID-19. Nat Cancer 2020;1:946-64. [DOI: 10.1038/s43018-020-00122-3] [Cited by in Crossref: 28] [Cited by in F6Publishing: 7] [Article Influence: 28.0] [Reference Citation Analysis]
167 Carrozzo M, Eriksen JG, Bensadoun RJ, Boers-Doets CB, Lalla RV, Peterson DE. Oral Mucosal Injury Caused by Targeted Cancer Therapies. J Natl Cancer Inst Monogr 2019;2019:lgz012. [PMID: 31425602 DOI: 10.1093/jncimonographs/lgz012] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
168 Manito N, Kaplinsky EJ, Bernat R, Roca J, Castells E, Serrano T, Esplugas E. Fatal interstitial pneumonitis associated with sirolimus therapy in a heart transplant recipient. The Journal of Heart and Lung Transplantation 2004;23:780-2. [DOI: 10.1016/j.healun.2003.07.008] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 1.7] [Reference Citation Analysis]
169 Lisik W, Kahan BD. Inhibitors of mammalian target of rapamycin: mechanism of action explains efficacy and toxicity: . Current Opinion in Organ Transplantation 2004;9:369-82. [DOI: 10.1097/01.mot.0000146725.34815.ea] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
170 Ratkovic M, Basic-jukic N, Radunovic D. Possible Sirolimus-Induced Acute Pancreatitis in a Renal Transplant Recipient: Sirolimus-induced Pancreatitis. Ther Apher Dial 2016;20:208-9. [DOI: 10.1111/1744-9987.12371] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]